These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21209614)

  • 1. Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs.
    Stingl Kirchheiner JC; Brockmöller J
    Clin Pharmacol Ther; 2011 Feb; 89(2):198-209. PubMed ID: 21209614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics in Europe: barriers and opportunities.
    Gurwitz D; Zika E; Hopkins MM; Gaisser S; Ibarreta D
    Public Health Genomics; 2009; 12(3):134-41. PubMed ID: 19204415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug development: assessment of pharmacogenetic studies by Spanish research ethics committees.
    Dal-Ré R; Luque I; Torres R; Lahuerta J
    Pharmacogenomics J; 2009 Apr; 9(2):86-9. PubMed ID: 19079365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
    Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
    Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics: role in medicines approval and clinical use.
    Novelli G; Borgiani P; Ciccacci C; Di Daniele N; Sirugo G; Papaluca Amati M
    Public Health Genomics; 2010; 13(5):284-91. PubMed ID: 19815999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?
    Kirchheiner J; Fuhr U; Brockmöller J
    Nat Rev Drug Discov; 2005 Aug; 4(8):639-47. PubMed ID: 16056390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing.
    Deverka PA; McLeod HL
    Clin Pharmacol Ther; 2008 Aug; 84(2):191-3. PubMed ID: 18679180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics: practices and opportunities for study design and data analysis.
    Flynn AA
    Drug Discov Today; 2011 Oct; 16(19-20):862-6. PubMed ID: 21875683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mobilizing pharmacogenomic analyses during clinical trials in drug development.
    Bienfait KL; Shaw PM; Murthy G; Warner AW
    Pharmacogenomics; 2013 Jul; 14(10):1227-35. PubMed ID: 23859576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of opioid pharmacogenetics.
    Argoff CE
    Clin J Pain; 2010 Jan; 26 Suppl 10():S16-20. PubMed ID: 20026961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Affymetrix DMET platform and pharmacogenetics in drug development.
    Deeken J
    Curr Opin Mol Ther; 2009 Jun; 11(3):260-8. PubMed ID: 19479659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic advantage of pharmacogenomics - clinical trials with genetic information.
    Ohashi W; Mizushima H; Tanaka H
    Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing pharmacogenetic evidence throughout clinical development.
    Burns DK
    Clin Pharmacol Ther; 2010 Dec; 88(6):867-70. PubMed ID: 20981004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics in drug development.
    McCarthy AD; Kennedy JL; Middleton LT
    Philos Trans R Soc Lond B Biol Sci; 2005 Aug; 360(1460):1579-88. PubMed ID: 16096107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of antihypertensive treatment.
    Arnett DK; Claas SA; Glasser SP
    Vascul Pharmacol; 2006 Feb; 44(2):107-18. PubMed ID: 16356784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hierarchy of research design used to categorize the "strength of evidence" in answering clinical dental questions.
    Jacob RF; Carr AB
    J Prosthet Dent; 2000 Feb; 83(2):137-52. PubMed ID: 10668024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.